全文获取类型
收费全文 | 10548篇 |
免费 | 501篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 116篇 |
儿科学 | 180篇 |
妇产科学 | 226篇 |
基础医学 | 1218篇 |
口腔科学 | 272篇 |
临床医学 | 788篇 |
内科学 | 2851篇 |
皮肤病学 | 150篇 |
神经病学 | 1129篇 |
特种医学 | 300篇 |
外科学 | 1350篇 |
综合类 | 25篇 |
一般理论 | 3篇 |
预防医学 | 469篇 |
眼科学 | 206篇 |
药学 | 724篇 |
中国医学 | 14篇 |
肿瘤学 | 1085篇 |
出版年
2024年 | 10篇 |
2023年 | 65篇 |
2022年 | 146篇 |
2021年 | 266篇 |
2020年 | 165篇 |
2019年 | 215篇 |
2018年 | 242篇 |
2017年 | 216篇 |
2016年 | 244篇 |
2015年 | 266篇 |
2014年 | 360篇 |
2013年 | 538篇 |
2012年 | 774篇 |
2011年 | 792篇 |
2010年 | 430篇 |
2009年 | 420篇 |
2008年 | 728篇 |
2007年 | 774篇 |
2006年 | 757篇 |
2005年 | 723篇 |
2004年 | 704篇 |
2003年 | 625篇 |
2002年 | 567篇 |
2001年 | 86篇 |
2000年 | 69篇 |
1999年 | 67篇 |
1998年 | 112篇 |
1997年 | 79篇 |
1996年 | 79篇 |
1995年 | 78篇 |
1994年 | 73篇 |
1993年 | 63篇 |
1992年 | 44篇 |
1991年 | 32篇 |
1990年 | 35篇 |
1989年 | 29篇 |
1988年 | 21篇 |
1987年 | 20篇 |
1986年 | 21篇 |
1985年 | 17篇 |
1984年 | 20篇 |
1983年 | 22篇 |
1982年 | 17篇 |
1981年 | 25篇 |
1980年 | 11篇 |
1979年 | 7篇 |
1978年 | 8篇 |
1977年 | 6篇 |
1974年 | 5篇 |
1972年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
Pigullo S Ferretti E Lanciotti M Bruschi M Candiano G Svahn J Haneline L Dufour C Pistoia V Corcione A 《British journal of haematology》2007,136(2):315-318
Tumour necrosis factor (TNF) contributes to the pathogenesis of bone marrow failure in Fanconi anaemia (FA) patients. The sensitivity of haematopoietic cells from FA, complementation group A (FANCA) subjects, who represent the majority of FA patients, to TNF-related apoptosis-inducing ligand (TRAIL) is unknown. The human lymphoblastoid FANCA HSC072 cell line and the genetically corrected counterpart HSC072FANCA-neo were tested for apoptoptic response to TRAIL using flow cytometry and Western blotting. FANCA cells were more sensitive to TRAIL-induced apoptosis than their corrected counterparts, indicating that TRAIL negatively regulates haematopoietic FANCA cell lines. This effect involved poly(ADP-ribose) polymerase-1 cleavage and caspase-8 activation. 相似文献
993.
Pineda-Roman M Bolejack V Arzoumanian V Anaissie E van Rhee F Zangari M Walker R Hollmig K Shaughnessy JD Epstein J Krishna S Crowley J Barlogie B 《British journal of haematology》2007,136(3):393-399
Complete response (CR) is still considered an important surrogate marker for outcome in multiple myeloma (MM). Long-term survival after transplantation, however, has been observed in a substantial proportion of patients who never achieved CR. The tandem transplant trial, Total Therapy 2, enrolled 668 patients, who were randomised up-front to thalidomide (THAL) or no THAL; 56 patients were identified as having had, for at least 6 months prior to initiation of therapy, monoclonal gammopathy of undetermined significance (MGUS, n = 21), smouldering MM (SMM, n = 22) or solitary plasmacytoma of bone (SPC, n = 13). The clinical characteristics and outcomes of patients with such 'evolved' MM (E-MM) and of those with 'unknown' prior history (U-MM) were compared. Fewer patients with MGUS/SMM-E-MM had anaemia or renal failure; CR was lower (22% vs. 48%) but 4-year estimates of event-free survival (54% vs. 56% with U-MM) and overall survival (65% vs. 70% with U-MM) were similar to those with SPC-E-MM or U-MM. In the latter group, achieving CR was associated with prolonged survival. In comparison with U-MM, E-MM evolved from MGUS/SMM was associated with lower CR rate without adversely affecting survival. In contrast, CR was an independent favourable feature for survival in U-MM. 相似文献
994.
Cardinale D Colombo A Sandri MT Lamantia G Colombo N Civelli M Salvatici M Veronesi G Veglia F Fiorentini C Spaggiari L Cipolla CM 《Circulation》2007,115(11):1339-1344
995.
Raffaele Addeo Michele Caraglia Vincenzo Faiola Elena Capasso Bruno Vincenzi Liliana Montella Rosario Guarrasi Luigi Caserta Salvatore Del Prete 《BMC cancer》2007,7(1):18
Background
Brain metastases (BM) represent one of the most frequent complications related to cancer, and their treatment continues to evolve. We have evaluated the activity, toxicity and the impact on Quality of Life (QoL) of a concomitant treatment with whole brain radiotherapy (WBRT) and Temozolomide (TMZ) in patients with brain metastases from solid tumors in a prospective Simon two stage study. 相似文献996.
The medicinal properties of extracts from the hemp plant Cannabis sativa have been known for centuries but only in the 90s membrane receptors for the Cannabis major principle were discovered in mammalian cells. Later on the endogenous ligands for the cannabinoid receptors were identified and the term 'endocannabinoid system' was coined to indicate the complex signaling system of cannabinoid receptors, endogenous ligands and the enzymes responsible for their biosynthesis and inactivation. The 'endocannabinoid system' is involved in a broad range of functions and in a growing number of pathological conditions. There is increasing evidence that endocannabinoids are able to inhibit cancer cell growth in culture as well as in animal models. Most work has focused on the role of endocannabinoids in regulating tumor cell growth and apoptosis and ongoing research is addressed to further dissect the precise mechanisms of cannabinoid antitumor action. However, endocannabinoids are now emerging as suppressors of angiogenesis and tumor spreading since they have been reported to inhibit angiogenesis, cell migration and metastasis in different types of cancer, pointing to a potential role of the endocannabinoid system as a target for a therapeutic approach of such malignant diseases. The potential use of cannabinoids to retard tumor growth and spreading is even more appealing considering that they show a good safety profile, regarding toxicity, and are already used in cancer patients as palliatives to stimulate appetite and to prevent devastating effects such as nausea, vomiting and pain. 相似文献
997.
Majolino I Davoli M Carnevalli E Locasciulli A Di Bartolomeo P Scimè R Corradini P Selleri C Narni F Musso M Bregni M Olivieri A De Fabritiis P Pogliani L Arbelaez JE Ruscio C Bacigalupo A;Gitmo Institutions 《Leukemia & lymphoma》2007,48(4):759-766
Fifty-three patients with multiple myeloma (MM) underwent an allogeneic stem cell transplant (HSCT) from their HLA identical siblings using a reduced-intensity conditioning consisting of thioteopa 5 mg/kg, fludarabine 90 mg/m(2), and melphalan 80 mg/m(2). Their median age was 52 years (range 38 - 68) and the interval from diagnosis 12 months. Forty-three patients (82%) had advanced disease and 33 had previously been treated with high-dose therapy with one (N = 21), or more (N = 12) autologus transplants. Ten (18%) had their allograft programmed after induction chemotherapy. The majority (N = 44) received peripheral blood as stem cell source. Acute graft-versus-host disease (GVHD) grade II - IV developed in 45%, but grade III - IV in only 5%. Cumulative incidence of chronic GVHD was 64%. Sixty-two per cent were in complete remission (CR) following transplantation. Transplant-related mortality was 13%. Relapse incidence was 32%. With a median follow-up of 22 months, 3-year overall survival is 45% and progression free survival (PFS) 37%. The thiotepa, fludarabine, and melphalan conditioning regimen can produce remissions in the majority of MM patients with a limited transplant mortality rate. When used as first line treatment the results of transplantation appear even more encouraging. 相似文献
998.
Bardelli M Leucci E Schürfeld K Bellan C Passiatore G Rocchigiani M Bartolommei S Orlandini M Zagursky J Lazzi S De Falco G Tosi P Oliviero S Leoncini L 《Leukemia & lymphoma》2007,48(10):2014-2021
Vascular Endothelial Growth Factor (VEGF)-D is a member of the VEGF family of angiogenic growth factors that activate the Vascular Endothelial Growth Factor Receptor (VEGFR)-2 and VEGFR-3, which are mainly expressed in blood and lymphatic vessels. Here we have analyzed by using monoclonal antibodies, the expression of VEGF-D and its cognate receptor VEGFR-3 in normal and pathologic bone marrow and lymph node biopsies. This analysis revealed that VEGF-D is expressed in B cells of the germinal centers, scattered B and T blasts, myeloid progenitors, acute leukemia, several types of non Hodgkin lymphoma, and classical Hodgkin's lymphoma. In normal tissues VEGFR-3 was only expressed in fenestrated capillaries of bone marrow and in lymphatic vessels of lymph nodes, while in VEGF-D expressing tumors newly formed vessels, but not malignant cells, showed high VEGFR-3 expression. These data suggest that VEGF-D could contribute to leukemia and lymphoma growth via the induction of angiogenesis in bone marrow and lymphoid tissues. 相似文献
999.
Schiavina M Contini P Fabiani A Cinelli F Di Scioscio V Zompatori M Campidelli C Pileri SA 《Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders》2007,24(1):39-50
RATIONALE: Lymphangioleiomyomatosis (LAM) is a rare disease of unknown aetiology which mainly affects women of reproductive age. A growing body of evidence suggests a relation between the disease and estrogenic hormones. In particular, pregnancy and use of estrogens favour the progression of the disease, which is in turn slowed down by menopause. These observations suggested already in the past a treatment strategy based on hormonal manipulation: discontinuation of estrogens containing medications, avoiding pregnancy, inhibition of estrogens activity and induction of menopause. OBJECTIVES: In the present study, conducted on a relatively large population for a rare disease, we sought to show the hormonal manipulation's positive effects for the survival rate. METHODS: 36 women suffering from LAM were evaluated between January 1985 and March 2005. All our patients were treated with hormonal therapy, following different schemes. The response to the treatment was evaluated in all patients with arterial blood sampling, lung function tests (total body plethysmography, DLCO), measurement of the hormones in the blood, chest and abdomen CT scan. MEASUREMENTS AND MAIN RESULTS: The survival rate since the clinical onset was 97% at the 5 year timepoint, 90% at 10 years, and 71% at 25 years. Previous studies, conducted before the introduction of the hormonal treatment showed a survival rate of 20% at 10 years. CONCLUSIONS: Our results highlight the role of the hormonal manipulation as a mainstay in the treatment of LAM, with the capability of reducing mortality and improving the quality of life as well. 相似文献
1000.